A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
This is an open-label phase I study to evaluate the safety, tolerability, and initial efficacy of JS004 injection combined with Toripalimab Injection in patients with advanced solid tumors who have failed standard therapy.
Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer
DRUG: JS004|DRUG: Toripalimab Injection
The incidence of adverse events (AE) and serious adverse events (SAE) were assessed, Incidence and severity of adverse events (AE) and serious adverse events (SAE) as assessed according to NCI-CTCAE 5.0, as well as abnormalities in vital signs, electrocardiogram, and laboratory tests, 2 years
OS, Duration of Response, 2 years|DOR, Duration of Response, 2 years|DCR, Disease Control Rate, 2 years|PFS, Progression-free survival, 2 years|ORR, Overall Response Rate, 2 years|TTR, Time to remission, 2 years|TTP, time to progression, 2 years
ORR, Objective response rate based on iRECIST criteria (Version 2017);, 2 years|DOR, duration of response based on iRECIST criteria (Version 2017);, 2 years|DCR, disease control rate based on iRECIST criteria (Version 2017);, 2 years|PFS, progression-free survival based on iRECIST criteria (Version 2017);, 2 years
This is an open-label phase I study to evaluate the safety, tolerability, and initial efficacy of JS004 injection combined with Toripalimab Injection in patients with advanced solid tumors who have failed standard therapy.